Novel Drug Discovery & Development

The vision for Lupin's Novel Drug Discovery and Development (NDDD) Group is to discover, develop and commercialize new drugs that address disease areas with significantly unmet medical need. Lupin's NDDD efforts are focused in the areas of (i) Metabolic/Endocrine disorders, (ii) Pain and Inflammation, (iii) Autoimmune diseases, (iv) Central Nervous System disorders, (v) Cancer and (vi) Infectious diseases. The Company has identified multiple drug targets within each of the above disease areas. These targets have been selected after an in-depth evaluation of a number of parameters, from both scientific and commercial point of view, to ensure that the selected programs are robust and have a high probability of success. While many of these programs are first-in-class opportunities, a few programs have been initiated with a clear differentiation strategy to be best-in-class. As part of the overall NDDD strategy, the discovery outcomes from each of the programs are periodically reviewed by a panel of global experts with vast experience in these therapeutic areas.

Over the last two years, Lupin has set up state-of-the-art medicinal chemistry, biology, drug metabolism and pharmacokinetics (DMPK) and toxicology laboratories to handle programs of this magnitude. Major infrastructure enhancements include medicinal chemistry and analytical chemistry laboratories, a computational chemistry facility to support structure-based drug design, in vitro (e.g. robotic screening platform for rapid screening of compound libraries and electrophysiology platforms), in vivo (e.g. well-equipped facility to conduct CNS and pain drug discovery) and ADME capabilities. More importantly, over the past two years we have created and nurtured a brilliant pool of top-notch talent.

We have identified targets from which 10 new research programs spread across several disease areas are currently underway. 6 of the programs have already progressed to a lead-to-clinical candidate phase.

Major Highlights

• Transitioned one clinical candidate – novel compound progressed from discovery to development
• Nine leading therapeutic area global experts have joined our scientific and development advisory panels

Strong intellectual property creation and management strategy in place; a total of 50 patent applications filed to date subsequent to revamping of the Novel Drug Discovery & Development program

Therapeutic Targets